Arrowhead Pharmaceuticals Future Growth

Future criteria checks 0/6

Arrowhead Pharmaceuticals is forecast to grow earnings and revenue by 2.5% and 5.7% per annum respectively. EPS is expected to grow by 1% per annum. Return on equity is forecast to be -67.3% in 3 years.

Key information

2.5%

Earnings growth rate

0.96%

EPS growth rate

Biotechs earnings growth	22.0%
Revenue growth rate	5.7%
Future return on equity	-67.27%
Analyst coverage	Good
Last updated	10 Feb 2026

Recent future growth updates

Recent updates

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 06

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

May 18 Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

Earnings and Revenue Growth Forecasts

NasdaqGS:ARWR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2028	503	-482	-414	-432	9
9/30/2027	316	-600	-488	-537	13
9/30/2026	457	-485	-183	-271	14
12/31/2025	1,091	202	322	339	N/A
9/30/2025	829	-2	157	180	N/A
6/30/2025	573	-148	-18	22	N/A
3/31/2025	545	-144	10	61	N/A
12/31/2024	3	-640	-572	-491	N/A
9/30/2024	4	-599	-604	-463	N/A
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	N/A	173	N/A
6/30/2019	137	46	N/A	157	N/A
3/31/2019	95	10	N/A	132	N/A
12/31/2018	47	-29	N/A	136	N/A
9/30/2018	16	-54	N/A	-47	N/A
6/30/2018	14	-54	N/A	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARWR's forecast earnings growth (2.5% per year) is below the savings rate (3.4%).

Earnings vs Market: ARWR's earnings (2.5% per year) are forecast to grow slower than the US market (15.7% per year).

High Growth Earnings: ARWR's earnings are forecast to grow, but not significantly.

Revenue vs Market: ARWR's revenue (5.7% per year) is forecast to grow slower than the US market (10.3% per year).

High Growth Revenue: ARWR's revenue (5.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARWR is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/10 13:26
End of Day Share Price	2026/02/10 00:00
Earnings	2025/12/31
Annual Earnings	2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ying Huang	Barclays
William Pickering	Bernstein
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 15% to US$75.91

Price target increased by 7.4% to US$59.25

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Consensus EPS estimates fall by 221%

Consensus EPS estimates have been downgraded.

Recent updates

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 19, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.

Price target increased by 15% to US$75.91

Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in China

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Chairman notifies of intention to sell stock

Chairman recently sold US$12m worth of stock

Chairman notifies of intention to sell stock

Now 20% overvalued after recent price rise

Independent Director recently sold US$992k worth of stock

Price target increased by 7.4% to US$59.25

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Independent Director recently sold US$493k worth of stock

Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Consensus EPS estimates fall by 221%

Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, Inc

Consensus EPS estimates have been downgraded.

Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies

No longer forecast to breakeven

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Consensus EPS estimates fall by 65%

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Consensus EPS estimates fall from profit to US$0.11 loss, revenue upgraded

No longer forecast to breakeven

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Forecast to breakeven in 2025

Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of Plozasiran

Consensus EPS estimates increase by 17%

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity

Insufficient new directors

Consensus EPS estimates increase by 168%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 112%

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

New major risk - Revenue and earnings growth

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025

Chairman recently sold US$1.5m worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Is Finally Arriving

Chairman recently sold US$775k worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Insider notifies of intention to sell stock